SCHEMBL4347342

SCHEMBL4347342

COc1cc(NC(=O)Nc2cccc(F)c2O)cc(OC)c1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.59
KMT2A Q03164 6/20 0.59
POLB P06746 3/20 0.59
MAPT P10636 5/20 0.57
ALDH1A1 P00352 3/20 0.57
GFER P55789 1/20 0.57
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 3/20 0.53
BCHE P06276 2/20 0.51
PKM P14618 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
KDM4E B2RXH2 1/20 0.49
HTT P42858 1/20 0.49
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
LMNA P02545 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4346250 0.85 MEN1 (0.59) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL6228887 0.83 MAPT (0.51) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4347079 0.83 MAPT (0.49) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4348931 0.82 ALDH1A1 (0.56) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4353831 0.81 ALDH1A1 (0.47) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4349213 0.81 RAB9A (0.64) MEN1KMT2AMAPTALDH1A1RAB9A
SCHEMBL6228505 0.79 MAPT (0.54) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL29663729 0.78 MAPT (0.69) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4354067 0.77 MAPT (0.58) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4345397 0.77 TRPV1 (0.58) MEN1KMT2AMAPTALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MEN1 2168/4885KMT2A 2096/4885POLB 3571/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MEN1 3901/4885KMT2A 1254/4885POLB 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.